Skip to main content
Drug combo effective in treating triple-infected cohort, study finds
10/10/2018

Data from a 22-patient study that assessed the safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir over a 12-week period in patients with hepatitis B, hepatitis C genotype 3 and HIV showed that the direct-acting antiviral manifested an 87% sustained virologic response rate. Details were presented at the ACG Annual Scientific Meeting.

Full Story: